Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue (PEI)

27. juli 2020 oppdatert av: William H. Redd, Icahn School of Medicine at Mount Sinai

Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue During Hematopoetic Stem Cell Transplantation for Multiple Myeloma

A sample of 60 patients scheduled for HSCT in the treatment of MM will be recruited in the weeks to months prior to their hospitalization. Light therapy incorporating ambient Programmed Environmental Illumination (PEI) will be used in patient hospital rooms (during scheduled transplant) to control cancer-related fatigue (CRF). The FDA has certified that light therapy, like that used in this study, is a low-risk intervention. When admitted to the hospital for a stem cell transplant, there will be a light fixture in the hospital room which the researchers will be testing to see how it may affect cancer related fatigue, sleep quality, and other negative side effects often seen with the transplant and subsequent treatment. The light fixture will turn on and off by itself in the morning. There are two treatment arms used in the study, each of the arms uses different light intensities. The study treatment received, i.e. which of the two lights, will be chosen by chance, like flipping a coin. There is an equal chance of being given each study treatment. Participants will not be told which study treatment they are getting until after the study is completed. Each light will be turned on from 7 AM to 10AM every day during transplantation. While in the hospital, assessment of fatigue, sleep activity, depression, circadian rhythms, and quality of life will continue through the course of hospitalization (14-21 days of treatment, to determine immediate impact of sPI), then repeat at one month and three months post-discharge follow-ups (to determine lasting effects). Outcomes will be assessed through standardized scales (e.g., FACIT-Fatigue Scale) and objective measures (e.g., actigraphy, daysimeter for light monitoring, melatonin from urine collection, blood inflammatory markers, all explained below). This trial will: 1) be the first randomized clinical trial (RCT) to investigate the effects of sPI to prevent CRF and other biopsychosocial side effects of transplant; 2) focus on a distinct, relatively homogenous patient population (MM-HSCT patients) with high prevalence of CRF; and 3) explore possible circadian rhythm mediation via melatonin analysis and blood analysis. This investigation will have major public health relevance as it will determine if an inexpensive and low patient burden intervention (sPI) is able to control fatigue associated with medical illnesses and related problems.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

73

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • New York
      • New York, New York, Forente stater, 10029
        • Icahn School of Medicine at Mount Sinai

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Who will undergo their first autologous HSCT procedure as treatment for multiple myeloma

AND:

  • Who are currently 21 years of age or older
  • English language proficient
  • Able to provide informed consent

Exclusion Criteria:

  • Under age 21
  • Previous HSCT procedure (autologous or allogeneic)Pregnancy
  • Eye Diseases which limit the ability of light to be processed (e.g., untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or retina damage)
  • Secondary cancer diagnosis within the last 5 years
  • Severe sleep disorders (e.g., Narcolepsy)
  • History of bipolar disorder or manic episodes (which is a contra-indication for light treatment)
  • Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months)
  • Previous use of light therapy to alleviate fatigue or depressive symptoms

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PEI Experimental Light
Ambient light fixture installed in the patient's hospital room
Enhet: PEI Experimental Light
Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
Aktiv komparator: Comparison Light
Ambient light fixture installed in the patient's hospital room
Enhet: Comparison Light
Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
FACIT-Fatigue Scale
Tidsramme: Baseline, Day 2, 7, 14, 28 and 90
The FACIT-Fatigue scale is a13 item scale, full scale 0-52, with higher score indicating better functioning or less fatigue.
Baseline, Day 2, 7, 14, 28 and 90

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Multidimensional Fatigue
Tidsramme: up to 3 months
The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Tested for its psychometric properties in cancer patients receiving radiotherapy, patients with the chronic fatigue syndrome, psychology students, medical students, army recruits and junior physicians, it was found to have good Test-retest Reliability (r=0.80) and great Internal Consistency (Cronbach's alpha = 0.92).
up to 3 months
The Pittsburgh Sleep Quality Index
Tidsramme: Baseline, Day 30 and Day 90
The Pittsburgh Sleep Quality Index consists of 19 self-rated instrument full scale from 0-21, with higher score indicating poorer sleep quality.
Baseline, Day 30 and Day 90
SF-36 Scale
Tidsramme: Baseline and 30 days post hospital discharge
Quality of life assessed using the SF-36 scale. The SF-36 is a multi-purpose, short form health survey consisting of 36 questions. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability
Baseline and 30 days post hospital discharge
Number of Participants With Score 16 or Greater on CES-D (Center for Epidemiologic Studies Depression Scale)
Tidsramme: Baseline, Day 2, Day 7, and Day 14 post transplant
Number of participants with score 16 or greater on CES-D, 20 item questionnaire that reflects major dimensions of depression: depressed mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness; psychomotor retardation; loss of appetite; and sleep disturbance. Full score from 0- 20, with higher score indicating more symptomology.
Baseline, Day 2, Day 7, and Day 14 post transplant
CES-D (Center for Epidemiologic Studies Depression Scale)
Tidsramme: Baseline, Day 2, 7, 14, 28, and 90
CES-D, 20 item questionnaire that reflects major dimensions of depression: depressed mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness; psychomotor retardation; loss of appetite; and sleep disturbance. Full score from 0- 20, with higher score indicating more symptomology.
Baseline, Day 2, 7, 14, 28, and 90
The Positive and Negative Affect Schedule (PANAS)
Tidsramme: Baseline, Day 30, Day 90
PANAS is a 20-item self-report measure of positive and negative affect. Each item rated on a 5-point scale of 1 (not at all) to 5 (extremely), each subscale from 1-5, full score from 1-5, with higher score indicating more symptoms. Change in PANAS at Day 30 and Day 90 as compared to baseline.
Baseline, Day 30, Day 90
Change in Brief Symptoms Inventory-18 (BSI-18)
Tidsramme: Baseline and Day 90
Brief Symptom Inventory-18 (BSI-18) - self-report 18-item instrument. Raw scores on the BSI-18 are converted to t-scores based on gender-specific normative data from non-patient community dwelling U.S. adults. A T-score = 50 indicating average function compared to the reference population and a standard deviation of 10, with a higher score indicating more symptom.
Baseline and Day 90
Fatigue Line Scale
Tidsramme: baseline, day 2, 7, and 14
Simple numeric graphic rating scale, marked on a line numbering 0-100, with higher score indicating more fatigue. Replaces the FACIT fatigue scale for daily fatigue assessment during inpatient procedures.
baseline, day 2, 7, and 14
Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF)
Tidsramme: Baseline, Day 30 after Discharge, Day 90 after Discharge
Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF) is a 30-item short form of the MFSI that measures five dimensions: general, physical, emotional, mental fatigue, and vigor. Each item is rated on a five-point Likert scale from 0 (not at all) to 4 (extremely). The total MFSI-SF score ranges from 0-4, with a higher score indicating a higher fatigue level.
Baseline, Day 30 after Discharge, Day 90 after Discharge
Sleep Latency
Tidsramme: Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Sleep latency measured by actigraph - Sleep latency is the average period of time between bed time and sleep start time
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Sleep Efficiency
Tidsramme: Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Sleep efficiency measured by actigraph - Sleep efficiency is defined as the average percentage of time in bed actually spent sleeping
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Wake Time
Tidsramme: Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Wake time measured by actigraph. Wake time is the average number of minutes the participant spent awake each night during the 5 day period. Baseline assessments were taken before transplant and day 2 is two days after transplant which is at least one week after the baseline.
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Wake Percent
Tidsramme: Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Wake percent measured by actigraph - Wake percent is the average percent of each night spent awake
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Sleep Time
Tidsramme: Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Sleep time measured by actigraph. Sleep time - average number of minutes the participant was asleep each night during the 5 day period. Baseline assessments were taken before transplant and day 2 is two days after transplant which is at least one week after the baseline.
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Sleep Percent
Tidsramme: Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Sleep percent measured by actigraph. Sleep percent is the percent of time spent in bed that the participant is asleep.
Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge
Melatonin
Tidsramme: Baseline and Discharge
Melatonin level
Baseline and Discharge

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Icahn School of Medicine at Mount Sinai

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. juli 2016

Primær fullføring (Faktiske)

23. januar 2019

Studiet fullført (Faktiske)

23. januar 2019

Datoer for studieregistrering

Først innsendt

21. juni 2017

Først innsendt som oppfylte QC-kriteriene

22. juni 2017

Først lagt ut (Faktiske)

26. juni 2017

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

11. august 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. juli 2020

Sist bekreftet

1. juli 2020

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • GCO 15-2009

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på PEI Experimental Light

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Gabon

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

3
Abonnere